Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Since 2019, Bristol-Myers Squibb has acquired pharmaceutical companies worth more than $115 billion, allow...
Bristol Myers Squibb's big buys: $18.1 billion in 2 biotech deals
On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equity value of $14 billion.
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
The latest trading day saw Bristol Myers Squibb (BMY) settling at $51.22, representing a +0.02% change from its previous close.
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceu...
Bristol to Buy Drug Developer RayzeBio for $4.1 Billion
Bristol Myers Squibb Co. agreed to buy radiological drug developer RayzeBio Inc. for about $4.1 billion, the latest deal in a buying spree to bolster its pipeline. Bloomberg's Madison Mueller reports.
The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio
Jared Hopkins, Wall Street Journal, joins 'The Exchange' to discuss Bristol-Myers Squibb's plan to buy RayzeBio.
Bristol Myers Squibb Buys RayzeBio, Its Second Multibillion-Dollar Deal in Days
RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying the radiopharmaceutical therapy company for $4.1 billion to expand its cancer treatment optio...
Midday Movers: Intel's Israel Deal, Bristol-Myers Squibb Buys RayzeBio
Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, and Nasdaq were all in positive ter...
Bristol Myers Squibb goes back to the acquisition well with $4.1B purchase of RayzeBio
Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) has made its second major acquisition in the span of a week, this time buying cancer drug developer RayzeBio in a $4.1 billion deal. The deal ...
Bristol Myers to buy RayzeBio for about $4.1B
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
RayzeBio is being bought for $62.50 a share in cash.
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion
Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Mye...
6 Reasons to Avoid Johnson & Johnson (JNJ) At All Costs
Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.
Related Companies